Conteduca V, Ku SY, Puca L, Slade M, Fernandez L, Hess J, Bareja R, Vlachostergios PJ, Sigouros M, Mosquera JM, Sboner A, Nanus DM, Elemento O, Dittamore R, Tagawa ST, Beltran H.Mol Cancer Ther. 2020 May;19(5):1157-1164. DOI: 10.1158/1535-7163
Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ.Clin Cancer Res. 2020 Apr 27. DOI: 10.1158/1078-0432.CCR-19-4100
Using nonenrichment-based, potentially more sensitive Epic Sciences circulating tumor cell (CTC) platform, we sought to detect and characterize CTCs in untreated, high-risk localized prostate cancer and to evaluate their clinical implication.
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine 20 Mar 2019. DOI: 10.1126/scitranslmed.aav0891
BLOG: EPIC IMPACT
EPIC PODCAST: FEATURED
In Episode 2 of Innovations in Cancer, we speak with Lauren Leiman, executive director at BloodPAC, the Blood Profiling Atlas in Cancer (BloodPAC) Consortium, launched October 2017, to accelerate the development and validation of liquid biopsy assays to improve the outcomes of patients with cancer. Lauren discusses the collaborative infrastructure that enables sharing of information between stakeholders in industry, academia, and regulatory agencies with the goal to standardize liquid biopsies to improve outcomes for patients.Listen Now